\n
\n
\n
Presentation:
\n
Ancor-2.5 Tablet: Each tablet contains Bisoprolol Fumarate USP 2.5 mg. Ancor-5 Tablet: Each tablet contains Bisoprolol Fumarate USP 5 mg. Ancor-10 Tablet: Each tablet contains Bisoprolol Fumarate USP 10 mg.
\n
\n
\n
\n
Indication:
\n
Hypertension, angina and adjunct in stable moderate to severe heart failure
\n
\n
\n
\n
Dosage & Administration:
\n
Hypertension and angina: Usually 5-10 mg once daily, max. 20 mg daily, Moderate to severe heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max.10 mg daily.
\n
\n
\n
\n
Contrainidications:
\n
In patients with cardiogenic shock, overt heart failure, second or third degree A-V block, right ventricular failure secondary to pulmonary hypertension and sinus bradycardia.
\n
\n
\n
\n
Warning & Precautions:
\n
Monitoring of renal, hepatic, and hematopoietic function should be performed at regular intervals during long-term treatment with bisoprolol.
\n
\n
\n
\n
Side effects:
\n
Gastro-intestinal disturbances, bradycardia, hypotension, peripheral vasoconstriction, headache, fatigue, sleep disturbances, dizziness, vertigo, sexual dysfunction; thrombocytopenia; visual disturbances, alopecia may be occurred.
\n
\n
\n
\n
Drug interaction:
\n
Bisoprolol should not be combined with other beta-blocking agents.
\n
\n
\n
\n
Use in special groups:
\n
Use in pregnancy: The safety of bisoprolol during pregnancy has not been established Use in lactation: No data is available for lactation. Use in children: Safety and effectiveness in children have not been established.
\n
\n
\n
\n
Packing:
\n
Ancor-2.5 Tablet: Each box contains 30’s tablets in blister pack. Ancor-5 Tablet: Each box contains 30’s tablets in blister pack. Ancor-10 Tablet: Each box contains 10’s tablets in blister pack
\n
\n